Briumvi Side Effects

Generic name: ublituximab

Medically reviewed by Drugs.com. Last updated on Jul 17, 2023.

Note: This document contains side effect information about ublituximab. Some dosage forms listed on this page may not apply to the brand name Briumvi.

Applies to ublituximab: intravenous solution.

Serious side effects of Briumvi

Along with its needed effects, ublituximab (the active ingredient contained in Briumvi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ublituximab:

More common

Body aches or pain
chest pain or tightness
chills
cough
cough producing mucus
diarrhea
dizziness
dryness or soreness of the throat
ear congestion
facial swelling
fever or chills
general feeling of discomfort or illness
headache
hoarseness
joint pain
loss of voice
muscle aches and pains
nausea or vomiting
pain or tenderness around the eyes and cheekbones
skin rash
sneezing
stuffy or runny nose
sweating
tender, swollen glands in the neck
trouble breathing
trouble in swallowing
trouble sleeping
unusual tiredness or weakness
voice changes
vomiting

Incidence not known

Back pain
blurred vision
confusion
dark urine
drowsiness
light-colored stools
seizures
upper right abdominal or stomach pain
yellow eyes and skin

Other side effects of Briumvi

Some side effects of ublituximab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Pain in the arms or legs

For Healthcare Professionals

Applies to ublituximab: intravenous solution.

General

The most common adverse reactions, with a frequency of 10% or greater, were infusion reactions and upper respiratory tract infections. The most common cause that led to treatment discontinuation was infection.

Immunologic

Common (1% to 10%): Herpes virus-associated infections^[Ref]

Musculoskeletal

Common (1% to 10%): Pain in extremity^[Ref]

Other

Very common (10% or more): Infusion reactions (48%), decreased neutrophil levels (15%)

Common (1% to 10%): Fatigue

Frequency not reported: Decreased immunoglobulins^[Ref]

-The most reported infusion reaction symptoms, with a frequency of 5% or greater, include pyrexia, chills, headache, and influenza-like illness.

-Serious infusion reactions occurred in 0.6% of patients.^[Ref]

Psychiatric

Common (1% to 10%): Insomnia^[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infections (45%)

Common (1% to 10%): Lower respiratory tract infections^[Ref]

-Upper respiratory tract infections include nasopharyngitis, upper respiratory tract infection, respiratory tract infection (viral), pharyngitis, rhinitis, sinusitis, acute sinusitis, tonsillitis, laryngitis, chronic sinusitis, viral pharyngitis, viral rhinitis, viral upper respiratory tract infection, chronic tonsillitis, pharyngitis streptococcal, bacterial sinusitis, and bacterial tonsillitis.

-Lower respiratory tract infections include bronchitis, pneumonia, tracheitis, tracheobronchitis, COVID-19 pneumonia, bacterial bronchitis, and viral pneumonia.^[Ref]